Dr. Zakashansky on Repeat Exposure to PARP Inhibitors in Patients With Ovarian Cancer

Video

Konstantin Zakashansky, MD, discusses repeat exposure to PARP inhibition in patients with platinum-sensitive, relapsed ovarian cancer.

Konstantin Zakashansky, MD, gynecologic oncologist and associate professor of Obstetrics, Gynecology and Reproductive Science at Mount Sinai Health System, discusses repeat exposure to PARP inhibition in patients with platinum-sensitive, relapsed ovarian cancer.

There are data supporting the sequential usage of multiple PARP inhibitors in patients; however, this is still under clinical development, says Zakashansky. Although there are not a lot of data available on this approach, many have been doing this and responses have been reported. Because of the pharmacokinetics between the different PARP inhibitors, there may be an application for that sequential usage in combination with bevacizumab (Avastin) or with immunotherapy, adds Zakashansky.

Currently, numerous trials are examining the specific question of whether PARP inhibitors can be re-used in patients who have previously been exposed, concludes Zakashansky.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD